OCX - Oncocyte Corp Stock Price, Fair Value and News

2.52USD-0.01 (-0.40%)Delayed as of 30 Apr 2024, 10:06 am ET

Market Summary

USD2.52-0.01

Delayedas of 30 Apr 2024, 10:06 am

-0.40%

OCX Alerts

3 major insider buys recently.

OCX Stock Price

View Fullscreen

OCX RSI Chart

OCX Valuation

Market Cap

20.9M

Price/Earnings (Trailing)

-0.75

Price/Sales (Trailing)

2.92

EV/EBITDA

-0.46

Price/Free Cashflow

-0.89

OCX Price/Sales (Trailing)

OCX Profitability

Operating Margin

86.02%

EBT Margin

-346.89%

Return on Equity

-135.73%

Return on Assets

-37.09%

Free Cashflow Yield

-112.78%

OCX Fundamentals

OCX Revenue

Revenue (TTM)

7.2M

Rev. Growth (Yr)

14.6%

Rev. Growth (Qtr)

-26.81%

OCX Earnings

Earnings (TTM)

-27.8M

Earnings Growth (Yr)

64.44%

Earnings Growth (Qtr)

-146.45%

Breaking Down OCX Revenue

52 Week Range

2.53

(Low)(High)

Last 7 days

0.8%

Last 30 days

-13.6%

Last 90 days

-16.2%

Trailing 12 Months

-53.8%

How does OCX drawdown profile look like?

OCX Financial Health

Current Ratio

1.49

OCX Investor Care

Shares Dilution (1Y)

38.72%

Diluted EPS (TTM)

-3.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.5M	6.8M	7.1M	7.2M
2022	8.0M	6.2M	5.3M	2.0M
2021	2.3M	4.2M	4.6M	7.7M
2020	0	0	0	1.2M
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	293.0K
2016	0	0	0	0
2015	0	0	0	397.0K
2014	0	0	0	569.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Oncocyte Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	broadwood partners, l.p.	bought	7,057,690	2.9164	2,420,000	-
Apr 11, 2024	arno andrew	bought	99,999	2.95	33,898	-
Apr 11, 2024	riggs josh	bought	10,000	2.95	3,390	ceo and president
Apr 11, 2024	broadwood partners, l.p.	bought	-	-	-	-
Jun 30, 2023	gutfreund john peter	sold	-	-	-3,085,050	-
Jun 23, 2023	silverman lou	acquired	-	-	25,000	-
Jun 23, 2023	kingsley alfred d	acquired	-	-	20,000	-
Jun 23, 2023	last andrew j.	acquired	-	-	20,000	-
Jun 23, 2023	arno andrew	acquired	-	-	30,000	-
Jun 14, 2023	kingsley alfred d	bought	6,447	0.2149	30,000	-

Which funds bought or sold OCX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Lindbrook Capital, LLC	sold off	-100	-10.00	-	-%
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	unchanged	-	3.00	21.00	-%
Apr 18, 2024	Piscataqua Savings Bank	unchanged	-	11.00	73.00	-%
Apr 05, 2024	NBC SECURITIES, INC.	new	-	1,000	1,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-310	1,250	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.24	-129,395	619,683	-%
Feb 14, 2024	Coppell Advisory Solutions LLC	new	-	25.00	25.00	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-11.58	-1,000	2,000	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-48,393	-	-%
Feb 14, 2024	BROADWOOD CAPITAL INC	unchanged	-	-1,555,620	6,272,660	0.54%

Are Funds Buying or Selling OCX?

Are funds buying OCX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OCX

No. of Funds

OCX Alerts

3 major insider buys recently.

Unveiling Oncocyte Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 22, 2024	bio-rad laboratories, inc.	8.99%	1,200,109	SC 13G
Apr 15, 2024	broadwood partners, l.p.	37.6%	0	SC 13D/A
Feb 14, 2024	pura vida investments, llc	8.45%	708,172	SC 13G/A
Feb 14, 2024	awm investment company, inc.	9.1%	754,286	SC 13G/A
Apr 14, 2023	pura vida investments, llc	9.99%	16,641,824	SC 13G/A
Apr 07, 2023	broadwood partners, l.p.	33.3%	0	SC 13D/A
Feb 14, 2023	pura vida investments, llc	15.22%	18,056,274	SC 13G
Feb 14, 2023	pura vida investments, llc	15.22%	18,056,274	SC 13G/A
Feb 14, 2023	awm investment company, inc.	6.10%	7,254,222	SC 13G
Nov 25, 2022	norfield capital llc	5.5%	6,600,359	SC 13G

Recent SEC filings of Oncocyte Corp

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	DEF 14A	DEF 14A
Apr 25, 2024	D	D
Apr 22, 2024	SC 13G	Major Ownership Report
Apr 16, 2024	10-K	Annual Report
Apr 15, 2024	SC 13D/A	13D - Major Acquisition
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 12, 2024	8-K	Current Report
Apr 11, 2024	8-K	Current Report

Peers (Alternatives to Oncocyte Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.6B	23.7B	-1.16%	4.18%	41.49	7.69	-8.94%	-35.72%
IDXX	42.0B	3.7B	-6.41%	2.68%	49.69	11.47	8.72%	24.44%
A	40.9B	6.7B	-4.07%	3.07%	33.1	6.07	-2.81%	-6.58%
DGX	14.9B	9.3B	4.80%	0.50%	17.63	1.61	-3.29%	6.68%
MEDP	12.3B	2.0B	-0.97%	99.97%	39.25	6.25	25.57%	21.62%
CRL	11.9B	4.1B	-14.34%	22.08%	25.11	2.89	3.86%	-2.39%
NTRA	11.4B	1.1B	2.82%	85.41%	-26.12	10.49	31.99%	20.63%
EXAS	10.7B	2.5B	-14.89%	-8.26%	-52.27	4.27	19.93%	67.26%
MID-CAP
NEOG	2.7B	929.2M	-21.29%	-27.87%	1.7K	2.9	28.93%	111.61%
GH	2.2B	563.9M	-11.83%	-19.37%	-4.62	3.93	25.45%	26.76%
SMALL-CAP
CDNA	424.6M	280.3M	-22.57%	1.36%	-2.23	1.51	-12.89%	-148.37%
ACRS	86.5M	31.2M	-1.61%	-86.28%	-0.98	2.77	5.03%	-1.81%
APDN	65.4M	9.0M	839.02%	296.91%	-9.04	7.27	-53.31%	2.21%
AWH	41.1M	9.2M	7.42%	-36.33%	-2.46	4.49	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Oncocyte Corp News

Latest updates

Oncocyte Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-26.8%	314,000	429,000	463,000	5,959,000	274,000	67,000	237,000	1,424,000	3,589,000	984,000	2,030,000	1,124,000	503,000	555,000	143,000	-	-	-	-	-	-
Cost Of Revenue	157.2%	409,000	159,000	169,000	265,000	278,000	314,000	183,000	105,000	2,220,000	860,000	1,350,000	738,000	716,000	601,000	365,000	173,000	-	-	-	-	-
Gross Profit	-147.2%	-117,000	248,000	272,000	10,000	-27,000	-269,000	31,000	247,000	2,601,000	-866,000	-394,000	79,000	-	-46,000	-222,000	-	-	-	-	-	-
Operating Expenses	137.6%	16,062,000	6,761,000	8,566,000	-5,840,000	11,621,000	1,437,000	1,657,000	3,264,000	17,794,000	12,738,000	13,174,000	11,439,000	5,967,500	6,198,000	8,546,000	8,447,000	7,523,000	5,257,000	5,462,000	3,997,000	4,047,000
S&GA Expenses	-18.4%	582,000	713,000	805,000	695,000	334,000	405,000	127,000	266,000	3,309,000	2,931,000	2,673,000	2,254,000	1,874,000	1,568,000	1,562,000	1,490,000	1,011,000	630,000	318,000	205,000	270,000
R&D Expenses	16.6%	2,547,000	2,185,000	2,435,000	2,127,000	1,378,000	1,472,000	2,444,000	2,007,000	4,591,000	3,142,000	2,537,000	3,361,000	1,800,000	2,615,000	3,225,000	2,159,000	2,318,000	1,625,000	1,508,000	1,343,000	1,204,000
EBITDA Margin	-29.9%	-3.47	-2.67	-2.14	-1.16	-8.57	-7.74	-8.55	-8.03	-9.41	-9.43	-8.77	-14.59	-	-	-	-	-	-	-	-	-
Interest Expenses	-192.3%	-108,000	117,000	1,000	-10,000	-12,000	-14,000	-21,000	-30,000	-42,000	-50,000	-49,000	-68,000	-77,000	-78,000	-75,000	-22,000	16,500	135,000	167,000	-19,000	-49,500
Income Taxes	-	-	-	-	-	-	-	-	-	-97,000	-	-1,794,000	-7,564,000	159,000	-	-2,190,000	1,095,000	-	-	-	-	-
Earnings Before Taxes	-146.4%	-15,992,000	-6,489,000	-8,333,000	5,959,000	-12,017,000	-1,818,000	-1,364,000	-3,413,000	-35,788,000	-13,800,000	-12,287,000	-11,483,000	-6,468,000	-6,783,000	-9,108,000	-8,827,000	-7,954,000	-5,225,000	-5,383,000	-3,864,000	-
EBT Margin	-18.4%	-3.47	-2.93	-2.40	-1.41	-9.30	-7.97	-8.72	-8.13	-9.49	-9.49	-8.79	-14.56	-	-	-	-	-	-	-	-	-
Net Income	-146.4%	-15,992,000	-6,489,000	-8,333,000	3,033,000	-44,978,000	-9,333,000	-8,300,000	-10,291,000	-35,885,000	-13,800,000	-10,493,000	-3,919,000	-6,309,000	-6,783,000	-9,108,000	-7,732,000	-7,954,000	-5,225,000	-5,383,000	-3,864,000	-4,499,500
Net Income Margin	51.3%	-3.88	-7.97	-8.81	-9.11	-36.41	-12.00	-10.95	-8.78	-8.30	-6.11	-4.95	-7.37	-	-	-	-	-	-	-	-	-
Free Cashflow	-57.7%	-4,826,000	-3,061,000	-7,634,000	-10,474,000	-10,450,000	-12,255,000	-12,365,000	-14,838,000	-7,466,000	-11,377,000	-8,668,000	-10,677,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.2%	75.00	82.00	88.00	83.00	100	157	171	146	160	168	177	129	55.00	58.00	63.00	60.00	40.00	33.00	38.00	42.00	10.00
Current Assets	-36.8%	11.00	17.00	21.00	16.00	26.00	37.00	49.00	25.00	39.00	48.00	50.00	63.00	9.00	12.00	18.00	18.00	23.00	20.00	37.00	41.00	9.00
Cash Equivalents	-31.6%	9.00	14.00	17.00	12.00	20.00	32.00	45.00	20.00	33.00	43.00	47.00	59.00	7.00	10.00	17.00	17.00	22.00	19.00	36.00	39.00	8.00
Net PPE	-	5.00	-	-	-	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	1.00
Goodwill	-	-	-	-	-	-	19.00	19.00	19.00	19.00	18.00	24.00	9.00	9.00	9.00	9.00	9.00	-	-	-	-	-
Liabilities	26.1%	49.00	39.00	39.00	39.00	60.00	75.00	83.00	89.00	94.00	69.00	75.00	5.00	22.00	23.00	24.00	23.00	9.00	3.00	4.00	3.00	6.00
Current Liabilities	-10.4%	7.00	8.00	8.00	9.00	12.00	13.00	14.00	14.00	14.00	13.00	20.00	10.00	9.00	9.00	7.00	7.00	4.00	3.00	4.00	3.00	6.00
Shareholder's Equity	-45.5%	20.00	38.00	44.00	38.00	34.00	77.00	83.00	57.00	65.00	99.00	103	107	33.00	35.00	40.00	37.00	31.00	29.00	34.00	38.00	3.00
Retained Earnings	-6.4%	-289	-272	-266	-257	-260	-215	-206	-198	-187	-151	-138	-127	-123	-117	-110	-101	-93.74	-85.79	-80.57	-75.18	-71.32
Shares Outstanding	0.0%	8.00	8.00	8.00	6.00	6.00	6.00	6.00	5.00	5.00	4.00	4.00	4.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	19.00	-	-	-	69.00	-	-	-	298	-	-	-	70.00	-	-	-	47.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-101.9%	-4,562	-2,259	-6,832	-9,672	-9,648	-11,396	-11,247	-13,277	-7,065	-10,983	-8,058	-9,835	-6,144	-6,005	-6,961	-6,870	-5,306	-4,851	-2,840	-6,718	-2,456
Share Based Compensation	-20.4%	484	608	834	834	2,619	3,181	2,232	2,010	1,705	1,850	1,996	1,290	985	1,784	1,361	937	787	821	701	686	400
Cashflow From Investing	118.6%	241	-1,296	-	-	-802	-859	-1,118	-1,561	-401	-394	-4,894	-8,272	-498	-526	-4,533	-6,191	-1,216	-11,235	-11.00	47.00	-
Cashflow From Financing	0%	-30.00	-30.00	12,274	-28.00	-100	-528	36,789	-355	-269	8,215	547	69,871	3,493	28.00	11,713	7,565	10,850	-296	-580	37,894	-331

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OCX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenue	$ 1,503	$ 958
Cost of revenues	1,002	880
Cost of revenues – amortization of acquired intangibles	88	96
Gross profit (loss)	413	(18)
Operating expenses:
Research and development	9,294	7,301
Sales and marketing	2,795	1,132
General and administrative	11,182	21,881
Change in fair value of contingent consideration	(5,762)	(31,019)
Impairment losses	6,757
Goodwill impairment		18,684
Loss on disposal and held for sale assets	1,283
Total operating expenses	25,549	17,979
Loss from operations	(25,136)	(17,997)
Other (expenses) income:
Interest expense	(52)	(83)
Realized and unrealized loss on marketable equity securities, net	(61)	(471)
Other income (expenses), net	394	(61)
Total other income (expenses)	281	(615)
Loss from continuing operations	(24,855)	(18,612)
Loss from discontinued operations (Note 13)	(2,926)	(54,290)
Net loss	(27,781)	(72,902)
Less: dividends and accretion of Series A redeemable convertible preferred stock	(942)	(520)
Net loss attributable to common stockholders	$ (28,723)	$ (73,422)
Net loss from continuing operations per share: basic	$ (3.37)	$ (3.45)
Net loss from continuing operations per share: diluted	(3.37)	(3.45)
Net loss from discontinued operations per share: basic	(0.38)	(9.80)
Net loss from discontinued operations per share: diluted	(0.38)	(9.80)
Net loss attributable to common stockholders per share: basic	(3.75)	(13.25)
Net loss attributable to common stockholders per share: diluted	$ (3.75)	$ (13.25)
Weighted average shares outstanding: basic	7,651	5,540
Weighted average shares outstanding: diluted	7,651	5,540

OCX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 9,432	$ 19,993
Accounts receivable, net of allowance for credit losses of $5 and $154, respectively	484	2,012
Marketable equity securities		433
Prepaid expenses and other current assets	643	977
Assets held for sale	139
Current assets of discontinued operations (Note 13)		2,121
Total current assets	10,698	25,536
NONCURRENT ASSETS
Right-of-use and financing lease assets, net	1,637	2,179
Machinery and equipment, net, and construction in progress	3,799	8,672
Intangible assets, net	56,595	61,633
Restricted cash	1,700	1,700
Other noncurrent assets	463	371
TOTAL ASSETS	74,892	100,091
CURRENT LIABILITIES
Accounts payable	953	1,253
Accrued compensation	1,649	1,771
Accrued royalties	1,116	2,022
Accrued expenses and other current liabilities	452	1,817
Accrued severance from acquisition	2,314	2,314
Accrued liabilities from acquisition		109
Right-of-use and financing lease liabilities, current	665	815
Current liabilities of discontinued operations (Note 13)	45	2,005
Total current liabilities	7,194	12,106
NONCURRENT LIABILITIES
Right-of-use and financing lease liabilities, noncurrent	2,204	2,729
Contingent consideration liabilities	39,900	45,662
TOTAL LIABILITIES	49,298	60,497
Commitments and contingencies
Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at December 31, 2023 and 2022, respectively; aggregate liquidation preference of $5,296 and $6,091 as of December 31, 2023 and 2022, respectively	5,126	5,302
SHAREHOLDERS’ EQUITY
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding
Common stock, no par value, 230,000 shares authorized; 8,261 and 5,932 shares issued and outstanding at December 31, 2023 and 2022, respectively	310,295	294,929
Accumulated other comprehensive income	49	39
Accumulated deficit	(289,876)	(260,676)
Total shareholders’ equity	20,468	34,292
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 74,892	$ 100,091

About Oncocyte Corp

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

CEO	Mr. Joshua Riggs
WEBSITE	https://oncocyte.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	75

Oncocyte Corp Frequently Asked Questions

What is the ticker symbol for Oncocyte Corp? What does OCX stand for in stocks?

OCX is the stock ticker symbol of Oncocyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oncocyte Corp (OCX)?

As of Mon Apr 29 2024, market cap of Oncocyte Corp is 20.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCX stock?

You can check OCX's fair value in chart for subscribers.

What is the fair value of OCX stock?

You can check OCX's fair value in chart for subscribers. The fair value of Oncocyte Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oncocyte Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oncocyte Corp a good stock to buy?

The fair value guage provides a quick view whether OCX is over valued or under valued. Whether Oncocyte Corp is cheap or expensive depends on the assumptions which impact Oncocyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCX.

What is Oncocyte Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, OCX's PE ratio (Price to Earnings) is -0.75 and Price to Sales (PS) ratio is 2.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCX PE ratio will change depending on the future growth rate expectations of investors.